Still Looking For A Cancer Vaccine Breakthrough, Roche Signs $200m Vaccibody Deal
Claims First Neoantigen Clinical Response In Advanced Cancer
Genentech is forging ahead with neoantigen-targeting cancer vaccines, despite a recent disappointment with its BioNTech partnership 
